# Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

> **NCT00438841** · PHASE2 · UNKNOWN · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 43 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00438841
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-08
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2009-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438841, "Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00438841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*